L929, DC2.4, and Raw264.7 cells were used to assess viability and uptake. BMDCs were used to assess maturation (measured as expression of CD80, CD86, and CCR7).C57BL/6 mice bearing B16F10 tumours were used to assess anticancer effects of prophylactic or therapeutic subcutaneous vaccine injections given 7, 14, and 21 days before tumour inoculation or after tumour establishment. This evidence concerns the gene CD86 and neoplasm.